齐拉西酮在氯氮平所致体重增加中的应用

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (0 KB) HTML (39 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the application of Ziprasidone for weight gain induced by Clozapine in patients with schizophrenia.Methods A total of 80 patients with chronic schizophrenia were recruited from January 2017 to January 2018 in our hospital.Based on the random number table method, they were assigned to the study group (n=40)and the control group (n=40).The study group was treated with Ziprasidone combined with Clozapine, and the control group was treated with Clozapine.Body weight and body mass index were assessed between the two groups.Similarly,clinical efficacy and adverse drug reactions were assessed by using positive and negative syndrome scale (PANSS) and treatment emergent symptom scale (TESS), respectively.Results After 12 weeks of treatment, there was no significant difference in the rate of discontinuation between the two groups (P＞0.05).After 12 weeks of treatment, the body weight and body mass index of the patients and the total score of PANSS in the study group were lower than those in the control group, and the differences were statistically significant (P<0.05).There was no significant difference in the total score of TESS between the two groups (P>0.05).Conclusion Ziprasidone as a supplemental treatment is associated with weight loss in patients with schizophrenia who receiving the treatment of Clozapine.However, evidence-based medicine is needed to recommend it to clinical practice.

Key words： Ziprasidone Schizophrenia Clozapine Body weight Body mass index

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIN Xiao-ming
	YU Min
	LIANG Xiao-min
	HE Li-hua
	ZHANG Jie

Cite this article:

LIN Xiao-ming,YU Min,LIANG Xiao-min, et al. Application of Ziprasidone for weight gain induced by Clozapine[J]. 中国当代医药, 2020, 27(12): 132-135.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I12/132

[1]	Leucht S，Cipriani A，Spineli L，et al.Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia：a multiple-treatments meta-analysis[J].Lancet，2013，382（9896）：951-962.
[2]	Miyamoto S，Duncan GE，Marx CE，et al.Treatments for schizophrenia：a critical review of pharmacology and mechanisms of action of antipsychotic drugs[J].Mol Psychiatry，2005，10（1）：79-104.
[3]	Curtis J，Watkins A，Rosenbaum S，et al.Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis[J].Early Interv Psychiatry，2016，10（3）：267-276.
[4]	Correll CU，Solmi M，Veronese N，et al.Prevalence，incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness：a large-scale meta-analysis of 3，211，768 patients and 113，383，368 controls[J].World Psychiatry，2017，16（2），163-180.
[5]	Hennekens CH.Increasing global burden of cardiovascular disease in general populations and patients with schizophrenia[J].J Clin Psychiatry，2007，68 Suppl 4：4-7.
[6]	Hennekens CH，Hennekens AR，Hollar D，et al.Schizophrenia and increased risks of cardiovascular disease[J].Am Heart J，2005，150（6）：1115-1121.
[7]	Zheng W，Zheng YJ，Li XB，et al.Efficacy and safety of adjunctive aripiprazole in schizophrenia：Meta-analysis of randomized controlled trials[J].J Clin Psychopharmacol，2016，36（6）：1-12.
[10]	刘文庭，马效芝，苏淑贞，等.6种抗精神病药物治疗12周对体重、血糖、血脂及催乳素的影响[J].国际精神病学杂志，2013（2）：20-23.
[11]	Flaum M，Andreasen NC.Diagnostic criteria for schizophrenia and related disorders：options for DSM-Ⅳ[J].Schizophr Bull，17（1）：133-142.
[12]	Kay SR，Fiszbein A，Opler LA.The positive and negative syndrome scale （PANSS）for schizophrenia[J].Schizophr Bull，1987，13（2），261-276.
[16]	刘丽，孙剑，汪卫华，等.小剂量齐拉西酮对奥氮平所致精神分裂症患者代谢障碍的干预[J].中国健康心理学杂志，2014，22（8）：1124-1127.
[8]	Rossi A，Ca n as F，Fagiolini A，et al.Switching among Antipsychotics in Everyday Clinical Practice：Focus on Ziprasidone[J].Postgrad Med，2011，123（1）：135-159.
[9]	Thentu JB，Nirogi R，Bhyrapuneni G，et al.Simultaneous invivo receptor occupancy assays for serotonin 1A，2A，and dopamine 2 receptors with the use of non-radiolabelled tracers：proposed method in screening antipsychotics[J].J Pharmacol Toxicol Methods，2017，85：22-28.
[13]	Zhang XY，Zhou DF，Cao LY，et al.Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia：a randomized double-blind study[J].Int Clin Psychopharmacol，16（6）：325-330.
[14]	Kroeze WK，Hufeisen SJ，Popadak BA，et al.H1-histamine receptor affinity predicts short-term weight gain for typical and atypicalantipsychotic drugs[J].Neuropsychopharmacology，2003，28（12）：519-526.
[15]	Galling B，Roldán A，Hagi K，et al.Antipsychotic augmentation vs.monotherapy in schizophrenia：systematic review，meta-analysis and meta-regression analysis[J].World Psychiatry，2017，16（1）：77-89.
[17]	Rummel-Kluge C，Komossa K，Schwarz S，et al.Head-tohead comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia：a systematic review and meta-analysis[J].Schizophr Res，2010，123（2-3）：225-233.
[18]	林勇，姚明荣，金卫东，等.齐拉西酮巩固治疗精神分裂症患者的体重指数、腰围的变化[J].中华全科医学，2015，13（10）：1594-1596.
[19]	马建华，刘海军，葛维，等.齐拉西酮和喹硫平对首发精神分裂症患者体重及糖脂代谢的影响[J].中国健康心理学杂志，2013，21（10）：1467-1468.
[20]	Henderson DC，Fan X，Copeland PM，et al.Ziprasidone as an adjuvant for clozapine-or olanzapine-associated medical morbidity in chronic schizophrenia[J].Hum Psychopharmacol，2009，24（3）：225.
[21]	Li XB，Tang YL，Zheng W，et al.QT interval prolongation associated with intramuscular ziprasidone in chinese patients：A case report and a comprehensive literature review with Meta-analysis[J].Case Rep Psychiatry，2014，2014：489 493.
[22]	Ries R，Sayadipour A.Management of psychosis and agitation in medical-surgical patients who have or are at risk for prolonged QT interval[J].J Psychiatr Pract，2014，20（5）：338-344.